Matthew Frigault, MD
Hematology & Oncology · Boston, MANPI 1013283035
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $195,701 of the $210,312 with a category attached, or 93.1%. 20 manufacturers reported payments, led by Foundation Medicine, Inc. at 41.3% of the total. Reporting peaked in 2020 at $74,589 and has fallen 82.5% since, to $13,051 in 2025. Among hematology & oncology clinicians in MA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 128 payments — averaging $1643.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Foundation Medicine, Inc.$87K
- Gilead$26K
- Bristol Myers Squibb$16K
- Sobi, Inc$15K
- Novartis$14K
- Incyte Corporation$10K
- plus $42K from 14 others
Across 285 payments — averaging $18,307 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Swedish Orphan Biovitrum AB$2.4M
- Novartis$712K
- Janssen Research & Development, LLC$668K
- Gilead$530K
- Incyte Corporation$495K
- Gamida Cell Inc.$351K
- plus $36K from 1 others
What the payments were for
- Consulting fees$195,70193%
- Speaking & faculty fees$7,5334%
- Travel & lodging$5,1462%
- Food & beverage$1,8851%
- Education$460%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Foundation Medicine, Inc. | 23 | $86,897 |
| Gilead(2 entities) | 23 | $25,983 |
| Bristol Myers Squibb | 16 | $15,748 |
| Sobi, Inc | 7 | $14,631 |
| Novartis | 15 | $14,308 |
| Incyte Corporation | 10 | $10,357 |
| Mckesson Sourcing Services, Inc. | 11 | $7,407 |
| E.r. Squibb & Sons, L.L.C. | 5 | $6,730 |
| Astrazeneca UK Limited | 1 | $6,400 |
| Johnson & Johnson | 6 | $4,574 |
| Swedish Orphan Biovitrum AB | 1 | $4,163 |
| Novartis Pharma AG | 2 | $3,995 |
| Legend Biotech USA Inc. | 1 | $3,450 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $2,640 |
| Janssen Scientific Affairs, LLC | 1 | $1,090 |
| Kyowa Kirin, Inc. | 1 | $700 |
| Janssen Global Services, LLC | 1 | $505 |
| Terumo BCT, Inc. | 1 | $500 |
| Daiichi Sankyo Inc. | 1 | $192 |
| AstraZeneca | 1 | $43 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- FOUNDATIONONE CDX$86,897
- FOUNDATIONONE LIQUID$38,515
- FOUNDATIONFOCUS$38,515
- FOUNDATIONONE HEME$38,515
- FOUNDATIONONE$38,515
- Gamifant$14,338
- KYMRIAH$12,409
- Tecartus$8,672
- Yescarta$6,740
- JCAR017$6,481
- CARVYKTI$6,308
- CTL_KYMRIAH_ONCOLOGY$2,350
- IMBRUVICA$505
- Quantum Cell Expansion System$500
- Enhertu$192
- JAKAFI$122
How this compares
$210,312 in reported general payments places this provider in the 90th percentile of 374 hematology & oncology providers in Massachusetts.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 47 | $292 |
| Acyclovir | 32 | $272 |
Paid to pharmacies, not to this prescriber.
Other hematology & oncology in Boston
- David ScaddenBoston$2.6M
- Sara TolaneyBoston$799K
- Matthew DavidsBoston$693K
- Julio HajdenbergBoston$583K
- Paul RichardsonBoston$523K
- Seth WanderBoston$464K
- Corey CutlerBoston$454K
- Hanny Al-SamkariBoston$412K
- Rupal BhattBoston$380K
- Matthew Vander HeidenBoston$355K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.